 "France's Urgo Group partners Eucare Pharma for wound care")
French international life sciences group Urgo has taken an equity stake in Eucare Pharmaceuticals, an Indian family owned company based in Chennai, to establish a strategic partnership in burns, advanced wound care, surgical hemostasis and dental regeneration concepts. An MoU to this effective was signed by two companies last week.
S Sridharan, managing director of Eucare Pharmaceuticals, said, “The fast growing medical needs and healthcare system mutation is now allowing the rise for premium treatment access. With the knowledge and experience accumulated in India since our creation 20 years ago, we will lead the way to provide better care to our compatriots. We will now benefit from Urgo’s global network in serving newer international markets. The partnership will enable us to access Urgo Group’s global expertise in the areas of clinical research, manufacturing, regulatory and marketing.”
As a global leader in the advanced would care (AWC) market, Urgo constantly looks for newer markets to strengthen its market position. Like in other Asian countries, India faces many healthcare challenges and the Indian population is not spared by the chronic or acute wound burden, offering significant potential for AWC concepts. With a rising number of diabetic patients, diabetic foot ulcer is already accountable for more than 25 million wounds to be treated every year in the country.
For over two decades, Eucare has pioneered in the area of acellular collagen technologies and drug delivery systems for burns, advanced wound management, surgical haemostasis and dental regeneration. Eucare has an established brand equity nationwide and built proprietary key account management targeting key hospital markets (corporate, public and military) with a strong distribution network. Eucare will benefit from world-expert in advanced wound care Urgo Group’s global network and expertise in innovation and pathology focused therapeutic offer.
By creating treatment tailored to each wound type, increasing education and awareness, Eucare and Urgo aim at becoming the caring partner to all major hospitals across the country.
“We are excited to set foot in India with the support and experience of our new partner. Eucare is a partner with strong market presence, manufacturing, regulatory and R&D capabilities. Urgo will now be able to provide its internationally recognised and scientifically proven TLC based wound dressing concepts to all Indian Patients,” said Pierre Moustial, general director, Urgo Group.
S Sridharan, managing director of Eucare Pharmaceuticals, said, “The fast growing medical needs and healthcare system mutation is now allowing the rise for premium treatment access. With the knowledge and experience accumulated in India since our creation 20 years ago, we will lead the way to provide better care to our compatriots. We will now benefit from Urgo’s global network in serving newer international markets. The partnership will enable us to access Urgo Group’s global expertise in the areas of clinical research, manufacturing, regulatory and marketing.”
As a global leader in the advanced would care (AWC) market, Urgo constantly looks for newer markets to strengthen its market position. Like in other Asian countries, India faces many healthcare challenges and the Indian population is not spared by the chronic or acute wound burden, offering significant potential for AWC concepts. With a rising number of diabetic patients, diabetic foot ulcer is already accountable for more than 25 million wounds to be treated every year in the country.
For over two decades, Eucare has pioneered in the area of acellular collagen technologies and drug delivery systems for burns, advanced wound management, surgical haemostasis and dental regeneration. Eucare has an established brand equity nationwide and built proprietary key account management targeting key hospital markets (corporate, public and military) with a strong distribution network. Eucare will benefit from world-expert in advanced wound care Urgo Group’s global network and expertise in innovation and pathology focused therapeutic offer.
By creating treatment tailored to each wound type, increasing education and awareness, Eucare and Urgo aim at becoming the caring partner to all major hospitals across the country.
“We are excited to set foot in India with the support and experience of our new partner. Eucare is a partner with strong market presence, manufacturing, regulatory and R&D capabilities. Urgo will now be able to provide its internationally recognised and scientifically proven TLC based wound dressing concepts to all Indian Patients,” said Pierre Moustial, general director, Urgo Group.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%